Clinical utility of anti-citrullinated peptide antibodies in patients with rheumatoid arthritis

ZHANG Songzhao,HUANG Hong,ZHANG Ying,WU Huaxiang,SHEN Jiangen

DOI: https://doi.org/10.3969/j.issn.0253-9934.2005.12.014

2005-01-01

Abstract:Objective To appraise the clinical utility of anti-citrullinated peptide antibodies(anti-ccp) in a cohort of patients with rheumatoid arthritis(RA). Methods Anti-ccp2 were detected with enzyme linked immunoassay(ELISA) in 163 serum samples(85 with RA,48 with non-RA,30 from healthy controls).The diagnostic ability of anti-ccp was expressed as a receiver operating characteristic(ROC) area under the curve(AUC).At the first visit from the patient's history,physical examination,blood and imaging tests were entered in a correlative analysis. Results The positive rate of anti-ccp with RA was 74.2%,and was significantly higher than that of the non-RA group(2.5%) and that of the controls group(0.0%,P<0.001).The ROC AUC of anti-ccp was 0.967 for diagnosis of RA,whereas the diagnostic ability of RF was significantly lower,with ROC AUC values of 0.809.There was no difference in the sensitivity of both anti-ccp and RF,but the specificity of anti-ccp was significantly greater than that of RF.There were no correlation and no statistical difference among the levels of anti-ccp and duration of disease and activity. Conclusions Anti-ccp antibody is an excellent serological marker for RA,which shows high diagnostic specificity and is detectable at an early stage,but the role of anti-ccp in the prediction of disease progression is yet to be investigated further.